Trial Profile
The Recommended Dose of Ertapenem is the Potential Risk of Neurotoxicity for Hemodialysis Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2016
Price :
$35
*
At a glance
- Drugs Ertapenem (Primary)
- Indications Bacterial infections; Renal failure
- Focus Adverse reactions; Pharmacokinetics
- 03 Mar 2016 New trial record